Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission (“SEC”) for the fiscal year ended March 31, 2019. The Company reported...
Mexco Energy Corporation (NYSE American: MXC) reported results on its Annual Report, Form 10-K to the Securities and Exchange Commission (“SEC”) for the fiscal year ended March 31, 2019. The Company reported...
If you own shares in Mexco Energy Corporation (NYSEMKT:MXC) then it's worth thinking about how it contributes to the...
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can make much more than 100% if the company does well. To wit, the Mexco Energy Corporation...
Gainers: PLAY +7.6% . OTCQB:HLIX +3.8% . EVC +2.8% . PTGX +2.3% . ODT +2.1% . More news on: Dave & Buster's Entertainment, Inc., Helix TCS, Inc., Entravision Communications Corporation,...
ADMA Biologics (NASDAQ: ADMA ) +46% as FDA approves ADMA Biologics' ASCENIV. More news on: ADMA Biologics, Inc., Sangamo Therapeutics, Inc., Riot Blockchain, Inc., Stocks on the move, Read more...
Mexco Energy Corporation (NYSEMKT:MXC), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MXCRead More...
Operating revenues in the third quarter of fiscal 2019 were $644,316, a 2% decrease from $654,931 for the third quarter of fiscal 2018 due primarily to decreased oil and gas prices. For the nine months...
Today we are going to look at Mexco Energy Corporation (NYSEMKT:MXC) to see whether it might be an attractive investment prospect. Specifically, we'll consider its Return On Capital Employed (ROCE), Read...
NEW YORK, Nov. 26, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Having recently attained GMP Certification at our European facility, MGC Pharma has commenced the full-scale commercial production of grade medical cannabis medicines containing THC and CBD APIs at its European production and compounding facility and will soon start clinical studies in epilepsy, based in Slovenia, in addition to the ongoing advancement of supplement and nutraceutical products. This is one more step in our Seed to Pharma strategy to become a leading BioPharma company with formulated medicines to sell into the global market. MGC also hopes to offer patients in Australia with these products and generate revenue from API sales.